# Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema

> **NCT07338097** · NA · ENROLLING_BY_INVITATION · sponsor: **CMH Multan Institute of Medical Sciences** · enrollment: 116 (estimated)

## Conditions studied

- Diabetic Macular Edema (DME)

## Interventions

- **DRUG:** Aflibercept (2.0 mg)
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07338097
- **Lead sponsor:** CMH Multan Institute of Medical Sciences
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-09-07
- **Primary completion:** 2026-02-07
- **Final completion:** 2026-02-07
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07338097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07338097, "Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07338097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*